Table 2.
Clinical and biochemical characteristics of MASLD-MASH and HCC patients related to the plasma cohort.
| Variable | All | F0/1 | F3 | Cirrhosis | HCC |
|---|---|---|---|---|---|
| Number of patients (male/female) | 78 (54/24) | 10 (7/3) | 6 (3/3) | 19 (8/11) | 43 (36/7) |
| Age (years) | 63 (20–84) | 40 (29–63) | 55 (20–63) | 58 (31–70) | 66 (53–84) |
| BMI (kg/m2) | 28.7 (21.2–45.7) | 26.5 (22.1–36.9) | 28.85 (23.4–32.3) | 28.9 (24.2–45.7) | 29.1 (21.2–40.8) |
| T2DM | 52.6% | 20.0% | 0% | 73.7% | 58.5% |
| AST (U/I) | 35 (16–273) | 32 (16–58) | 49 (25–77) | 32 (18–273) | 35.5 (18–248) |
| ALT (U/I) | 39 (10–273) | 51 (14–94) | 62 (35–154) | 44 (22–273) | 36.5 (10–152) |
| γ-GT (U/I) | 91 (15–554) | 79.5 (15–197) | 47 (28–317) | 77 (16–482) | 93 (22–554) |
| Albumin (g/L) | 4.0 (2.4–5.3) | 4.4 (4.0–5.3) | 4.35 (3.9–4.6) | 4.2 (3.9–4.6) | 3.7 (2.4–4.7) |
| Total bilirubin (mg/dL) | 0.8 (0.3–18.2) | 0.7 (0.3–0.9) | 0.9 (0.5–1.6) | 0.6 (0.3–1.5) | 1.2 (0.4–18.2) |
| Total cholesterol (mg/dL) | 166.5 (80–314) | 207 (162–314) | 192 (165–256) | 161 (130–267) | 165 (80–267) |
| Triglycerides (mg/dL) | 108 (64–812) | 156 (98–441) | 100 (66–159) | 120 (67–812) | 101 (64–275) |
| Child score | A 100% | ||||
| BCLC | 0: 11.6% A: 48.8% B: 20.9% C: 14.0% D: 4.7% |
||||
| Number of nodules | 2 (1–7) |